托法替布治疗溃疡性结肠炎：从临床试验到真实世界经验的疗效与安全性
Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience.
作者信息
D'Amico Ferdinando, Parigi Tommaso Lorenzo, Fiorino Gionata, Peyrin-Biroulet Laurent, Danese Silvio
机构信息
Department of Biomedical Sciences, Humanitas University, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Milan, Italy Department of Gastroenterology, Humanitas Clinical and Research Center, Milan, Italy.
出版信息
Therap Adv Gastroenterol. 2019 May 16;12:1756284819848631. doi: 10.1177/1756284819848631. eCollection 2019.
Abstract
Tofacitinib is an oral small molecule directed against the JAK/STAT pathway, blocking the inflammatory cascade. Oral formulation of tofacitinib has recently been approved for the treatment of patients with moderate-severe ulcerative colitis. Its efficacy and safety have been demonstrated in three phase III clinical trials and confirmed by promising real-life data. The purpose of this review is to summarize the available evidence on the efficacy and safety of tofacitinib and to define its role and position in the treatment algorithms for patients with ulcerative colitis.
摘要
托法替布是一种针对JAK/STAT通路的口服小分子药物，可阻断炎症级联反应。托法替布的口服制剂最近已被批准用于治疗中重度溃疡性结肠炎患者。其疗效和安全性已在三项III期临床试验中得到证实，并得到了有前景的真实世界数据的佐证。本综述的目的是总结关于托法替布疗效和安全性的现有证据，并明确其在溃疡性结肠炎患者治疗方案中的作用和地位。
相似文献
1
Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience.托法替布治疗溃疡性结肠炎：从临床试验到真实世界经验的疗效与安全性
Therap Adv Gastroenterol. 2019 May 16;12:1756284819848631. doi: 10.1177/1756284819848631. eCollection 2019.
2
Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy.评估枸橼酸托法替布治疗中重度活动性溃疡性结肠炎：治疗方案的设计、研发与定位
Clin Exp Gastroenterol. 2019 May 2;12:179-191. doi: 10.2147/CEG.S150908. eCollection 2019.
3
Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study.托法替布治疗难治性中重度溃疡性结肠炎：一项回顾性多中心观察性研究的真实世界经验
J Clin Med. 2020 Jul 10;9(7):2177. doi: 10.3390/jcm9072177.
4
Tofacitinib for the treatment of ulcerative colitis.托法替尼治疗溃疡性结肠炎。
Expert Rev Clin Immunol. 2018 Nov;14(11):881-892. doi: 10.1080/1744666X.2018.1532291. Epub 2018 Oct 11.
5
Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.奥卡维妥昔单抗维持治疗溃疡性结肠炎患者的治疗结局建模：OCTAVE 临床项目数据的事后分析。
Adv Ther. 2023 Oct;40(10):4440-4459. doi: 10.1007/s12325-023-02603-0. Epub 2023 Jul 31.
6
Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience.托法替布治疗哥伦比亚中重度溃疡性结肠炎的真实世界经验。
Gastroenterol Hepatol. 2023 Aug-Sep;46(7):512-521. doi: 10.1016/j.gastrohep.2022.10.020. Epub 2022 Nov 11.
7
Efficacy of tofacitinib treatment in ulcerative colitis.托法替布治疗溃疡性结肠炎的疗效。
Gastroenterol Hepatol. 2019 Jun-Jul;42(6):403-412. doi: 10.1016/j.gastrohep.2019.03.002. Epub 2019 May 14.
8
Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going.托法替布及新型JAK抑制剂在炎症性肠病中的应用现状与未来发展方向
Drugs Context. 2022 Apr 8;11. doi: 10.7573/dic.2021-11-4. eCollection 2022.
9
Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting.托法替尼治疗溃疡性结肠炎（TOUR）：在真实环境中启动托法替尼治疗后的早期应答。
Inflamm Bowel Dis. 2023 Apr 3;29(4):570-578. doi: 10.1093/ibd/izac121.
10
Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience.托法替布治疗儿童溃疡性结肠炎：一项回顾性多中心研究经验
Inflamm Bowel Dis. 2025 Feb 6;31(2):425-431. doi: 10.1093/ibd/izae112.
引用本文的文献
1
Tofacitinib-induced Hepatitis and Tuberculosis: A Case of Two Rare Adverse Events in a Single Patient.托法替布诱发的肝炎和肺结核：1例患者出现两种罕见不良事件
J Clin Exp Hepatol. 2025 Mar-Apr;15(2):102457. doi: 10.1016/j.jceh.2024.102457. Epub 2024 Nov 28.
2
Prescribed cumulative dosage of corticosteroids to patients with inflammatory bowel disease diagnosed between 2006 and 2020: a retrospective observational study.2006年至2020年间确诊的炎症性肠病患者的皮质类固醇规定累积剂量：一项回顾性观察研究。
Therap Adv Gastroenterol. 2024 Oct 13;17:17562848241288851. doi: 10.1177/17562848241288851. eCollection 2024.
3
Real world evidence on the effectiveness and safety of tofacitinib in ulcerative colitis in Lebanon.黎巴嫩溃疡性结肠炎中托法替布有效性和安全性的真实世界证据。
BMC Gastroenterol. 2024 Oct 4;24(1):349. doi: 10.1186/s12876-024-03341-5.
4
Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023.台湾溃疡性结肠炎的管理：2023年更新的台湾炎症性肠病学会共识指南
Intest Res. 2024 Jul;22(3):213-249. doi: 10.5217/ir.2023.00050. Epub 2024 Jul 29.
5
The Complex Relationship between Mechanisms Underlying Inflammatory Bowel Disease, Its Treatment, and the Risk of Lymphomas: A Comprehensive Review.炎症性肠病的潜在机制、其治疗方法与淋巴瘤风险之间的复杂关系：一项全面综述
Int J Mol Sci. 2024 Apr 11;25(8):4241. doi: 10.3390/ijms25084241.
6
Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis.托法替布治疗亚洲溃疡性结肠炎患者的真实世界疗效和安全性。
World J Gastroenterol. 2024 Apr 7;30(13):1871-1886. doi: 10.3748/wjg.v30.i13.1871.
7
Effect of Carbamylated Erythropoietin in a Chronic Model of TNBS-Induced Colitis.氨甲酰化促红细胞生成素在三硝基苯磺酸诱导的慢性结肠炎模型中的作用。
Biomedicines. 2023 Sep 9;11(9):2497. doi: 10.3390/biomedicines11092497.
8
Upfront tofacitinib in patients with biological-naïve ulcerative colitis - An Indian multicentric experience.初治生物制剂的溃疡性结肠炎患者使用托法替布的印度多中心经验
Indian J Gastroenterol. 2024 Feb;43(1):237-243. doi: 10.1007/s12664-023-01434-9. Epub 2023 Sep 20.
9
Quantitative analysis of JAK/STAT signaling pathway in patients of inflammatory skin disorders.炎症性皮肤病患者JAK/STAT信号通路的定量分析
Rheumatol Int. 2024 Dec;44(12):3009-3015. doi: 10.1007/s00296-023-05418-y. Epub 2023 Aug 10.
10
Protective effect of the novel calcineurin inhibitor voclosporin in experimental colitis.新型钙调神经磷酸酶抑制剂voclosporin对实验性结肠炎的保护作用。
Front Med (Lausanne). 2023 Jun 9;10:1177450. doi: 10.3389/fmed.2023.1177450. eCollection 2023.
本文引用的文献
1
Real-World Experience with Tofacitinib in IBD at a Tertiary Center.真实世界中在三级中心使用托法替布治疗炎症性肠病的经验。
Dig Dis Sci. 2019 Jul;64(7):1945-1951. doi: 10.1007/s10620-019-05492-y. Epub 2019 Feb 7.
2
Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis.中度至重度溃疡性结肠炎治疗的系统评价和网状Meta分析
Int J Clin Pharm. 2018 Dec;40(6):1411-1419. doi: 10.1007/s11096-018-0743-4. Epub 2018 Nov 26.
3
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.托法替尼诱导治疗可在 3 天内减轻溃疡性结肠炎患者的症状。
Clin Gastroenterol Hepatol. 2019 Jan;17(1):139-147. doi: 10.1016/j.cgh.2018.07.009. Epub 2018 Sep 10.
4
Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis.托法替尼治疗溃疡性结肠炎安全性数据库中母体/父体暴露的妊娠结局。
Inflamm Bowel Dis. 2018 Nov 29;24(12):2494-2500. doi: 10.1093/ibd/izy160.
5
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.接受托法替尼治疗的溃疡性结肠炎患者的带状疱疹感染。
Inflamm Bowel Dis. 2018 Sep 15;24(10):2258-2265. doi: 10.1093/ibd/izy131.
6
Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies.托法替布用于东亚活动性溃疡性结肠炎患者的诱导和维持治疗：三项3期多国研究的亚组分析
Intest Res. 2018 Apr;16(2):233-245. doi: 10.5217/ir.2018.16.2.233. Epub 2018 Apr 30.
7
Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.中重度溃疡性结肠炎治疗策略的成本-效果分析。
Inflamm Bowel Dis. 2018 Oct 12;24(11):2291-2302. doi: 10.1093/ibd/izy114.
8
Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.系统评价与网络荟萃分析：托法替布与生物疗法治疗中重度溃疡性结肠炎的比较评估。
Aliment Pharmacol Ther. 2018 Feb;47(4):454-465. doi: 10.1111/apt.14449. Epub 2017 Dec 4.
9
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.托法替布治疗溃疡性结肠炎患者的研究：3 期随机对照诱导和维持研究中的健康相关生活质量。
J Crohns Colitis. 2018 Jan 24;12(2):145-156. doi: 10.1093/ecco-jcc/jjx133.
10
Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.带状疱疹和托法替尼：临床结局和伴随治疗的风险。
Arthritis Rheumatol. 2017 Oct;69(10):1960-1968. doi: 10.1002/art.40189. Epub 2017 Sep 6.
Zotero 插件